JP2018503668A5 - - Google Patents

Download PDF

Info

Publication number
JP2018503668A5
JP2018503668A5 JP2017540549A JP2017540549A JP2018503668A5 JP 2018503668 A5 JP2018503668 A5 JP 2018503668A5 JP 2017540549 A JP2017540549 A JP 2017540549A JP 2017540549 A JP2017540549 A JP 2017540549A JP 2018503668 A5 JP2018503668 A5 JP 2018503668A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
phe
composition according
lys
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017540549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018503668A (ja
JP6613312B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/055305 external-priority patent/WO2016061087A1/en
Publication of JP2018503668A publication Critical patent/JP2018503668A/ja
Publication of JP2018503668A5 publication Critical patent/JP2018503668A5/ja
Application granted granted Critical
Publication of JP6613312B2 publication Critical patent/JP6613312B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017540549A 2014-10-14 2015-10-13 膵臓癌を処置するためのペプチドをベースとする方法 Expired - Fee Related JP6613312B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462063909P 2014-10-14 2014-10-14
US62/063,909 2014-10-14
PCT/US2015/055305 WO2016061087A1 (en) 2014-10-14 2015-10-13 Peptide-based methods for treating pancreatic cancer

Publications (3)

Publication Number Publication Date
JP2018503668A JP2018503668A (ja) 2018-02-08
JP2018503668A5 true JP2018503668A5 (enExample) 2018-11-22
JP6613312B2 JP6613312B2 (ja) 2019-11-27

Family

ID=54365375

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017540549A Expired - Fee Related JP6613312B2 (ja) 2014-10-14 2015-10-13 膵臓癌を処置するためのペプチドをベースとする方法
JP2017540551A Active JP7023709B2 (ja) 2014-10-14 2015-10-13 抗炎症特性を有するペプチド
JP2020118752A Pending JP2020180149A (ja) 2014-10-14 2020-07-09 抗炎症性組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017540551A Active JP7023709B2 (ja) 2014-10-14 2015-10-13 抗炎症特性を有するペプチド
JP2020118752A Pending JP2020180149A (ja) 2014-10-14 2020-07-09 抗炎症性組成物

Country Status (10)

Country Link
US (5) US10016480B2 (enExample)
EP (2) EP3206704B1 (enExample)
JP (3) JP6613312B2 (enExample)
KR (3) KR20230004907A (enExample)
CN (2) CN107580502B (enExample)
AU (2) AU2015333728B2 (enExample)
BR (1) BR112017007543A2 (enExample)
CA (2) CA2963478A1 (enExample)
WO (2) WO2016061087A1 (enExample)
ZA (1) ZA201702537B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JP6613312B2 (ja) * 2014-10-14 2019-11-27 ジ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシズ 膵臓癌を処置するためのペプチドをベースとする方法
WO2017149012A1 (en) * 2016-03-02 2017-09-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides and uses thereof for reducing cd95-mediated cell motility
JP2019513021A (ja) * 2016-03-24 2019-05-23 ナントセル，インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
WO2017194586A1 (en) 2016-05-10 2017-11-16 Université Pierre Et Marie Curie - Paris 6 (Upmc) Agents that activate cd47 and their use in the treatment of inflammation
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CA3027911A1 (en) 2016-06-30 2018-01-04 Nant Holdings Ip, Llc Coordinated treatment regimen to treat a tumor
CN106432014B (zh) * 2016-09-05 2019-08-16 中国医学科学院放射医学研究所 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用
US10799555B2 (en) 2016-09-15 2020-10-13 Leidos, Inc. PD-1 peptide inhibitors
US11103551B2 (en) * 2016-11-09 2021-08-31 Tang-Long Shen Method for treatment or prevention of a cancer
US20190358263A1 (en) * 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CN116983395A (zh) 2017-04-24 2023-11-03 河谷细胞有限公司 靶向性新表位载体及其方法
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3630807B1 (en) 2017-05-25 2025-08-13 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
EP3687559B1 (en) 2017-09-29 2025-11-12 Sanford Burnham Prebys Medical Discovery Institute Compositions that target tumor-associated macrophages and methods of use therefor
CN109745324B (zh) * 2017-11-06 2026-02-06 中国科学院上海营养与健康研究所 非经典NF-kB通路的小分子抑制剂及其应用
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
WO2019168524A1 (en) 2018-02-27 2019-09-06 Leidos, Inc. Pd-1 peptide inhibitors
US11823773B2 (en) 2018-04-13 2023-11-21 Nant Holdings Ip, Llc Nant cancer vaccine strategies
WO2019243906A1 (en) * 2018-06-20 2019-12-26 Universidade De Coimbra "(3s)- and (3r)-6,7-bis(hydroxymethyl)-1h,3h-pyrrolo[1,2-c]thiazoles as p53 activators"
EP3836955A4 (en) * 2018-08-15 2022-05-18 The Regents of the University of California IL-10 INHIBITION FOR VACCINES AND IMMUNOTHERAPY
CN112840211B (zh) * 2018-08-27 2024-11-12 南特生物公司 Rp182组合物及方法
US20220143130A1 (en) * 2018-08-29 2022-05-12 Riptide Bioscience, Inc. Peptides Having Immunomodulatory Properties
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
KR20260006040A (ko) * 2018-08-29 2026-01-12 립타이드 바이오사이언스, 인코포레이티드 면역조정 특성을 갖는 펩티드
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
US20200102356A1 (en) * 2018-10-01 2020-04-02 NMC Inc. Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants
US20220053773A1 (en) * 2018-10-01 2022-02-24 Innate Immunity LLC Compositions and methods for the treatment of pathogenic infections in plants
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same
CN121971599A (zh) 2019-02-25 2026-05-05 芝加哥大学 用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
CA3134420A1 (en) * 2019-04-12 2020-10-15 Riptide Bioscience, Inc. Methods for modulating macrophage activity
CA3138597A1 (en) * 2019-05-10 2020-11-19 The Regents Of The University Of California Modified pluripotent cells
JP7606471B2 (ja) 2019-05-22 2024-12-25 レイドス， インコーポレイテッド Ｌａｇ３結合ペプチド
EP3990000A1 (en) * 2019-06-28 2022-05-04 Nantcell, Inc. Pharmaceutical compositions to enhance phagocytosis without inflammation
CA3165339A1 (en) 2019-12-19 2021-06-24 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Cd206 modulators their use and methods for preparation
CN111116713B (zh) * 2020-01-07 2023-06-23 郑州大学 Sirpa蛋白亲和环肽及其应用
KR20220163940A (ko) 2020-02-04 2022-12-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-디니트로페놀 키메라 항원 수용체
US20230147468A1 (en) * 2020-03-31 2023-05-11 Innate Immunity LLC Recombinant peptide to treat fire blight
US11338040B2 (en) 2020-06-04 2022-05-24 Leidos, Inc. Immunomodulatory compounds
WO2022034523A1 (en) 2020-08-13 2022-02-17 Immunitybio, Inc. Phagocytosis-inducing compounds and methods of use
JP2023548662A (ja) 2020-10-12 2023-11-20 レイドス， インコーポレイテッド 免疫調節性ペプチド
AU2022300553B2 (en) * 2021-06-28 2025-06-19 Medi&Gene Inc. Peptide having antidiabetic activity and use thereof
CN117897393A (zh) * 2021-06-28 2024-04-16 高丽大学校产学协力团 具有抗癌活性的肽及其用途
CN115607674B (zh) * 2021-07-15 2023-09-19 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗胰腺癌的药物中的应用
WO2023080578A1 (ko) * 2021-11-05 2023-05-11 주식회사 레메디 상처 치료 및 항염증 활성을 가지는 펩타이드 및 이의 용도
WO2023097111A2 (en) * 2021-11-29 2023-06-01 Riptide Bioscience, Inc. Methods and compositions for treating calcinosis associated conditions
WO2023111695A1 (en) * 2021-12-16 2023-06-22 Ramakrishna Reddy Isanaka A stable anti-angiogenic and anti-inflammatory pharmaceutical formulation and pharmaceutical combination for treatment and prevention of psoriasis
KR102920640B1 (ko) 2022-03-11 2026-01-29 국립순천대학교산학협력단 항진균 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항진균용 조성물
WO2024102993A1 (en) * 2022-11-10 2024-05-16 Research Foundation Of The City University Of New York Cationically-enframed high density aromatic peptides
CN115838395A (zh) * 2022-11-15 2023-03-24 西北农林科技大学 具有可溶性环氧化物水解酶抑制作用的活性肽及其应用
CN116768970A (zh) * 2023-05-19 2023-09-19 重庆师范大学 抗氧化多肽、制备方法及其应用
CN117143183B (zh) * 2023-08-25 2024-08-16 广州益养生物科技有限公司 一种三肽、三肽盐或衍生物及其应用
EP4626453A1 (en) * 2023-10-30 2025-10-08 Ramakrishna Reddy Isanaka Peptide with anti-inflammatory and anti-microbial activity
WO2025255373A2 (en) * 2024-06-05 2025-12-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fatty acid and cyclized derivatives of the immunomodulatory peptide rp-182 with improved anti-tumor activity, compositions, and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970006154B1 (ko) 1987-07-06 1997-04-24 루이지아나 스테이트 유니버시티 아그리컬춰럴 앤드 메카니칼 컬리지 용해성 펩티드에 의한 진핵 병원체와 신생물의 억제 및 섬유아세포와 임파구의 자극
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
WO1990012866A1 (en) 1989-04-10 1990-11-01 Louisiana State University And Agricultural And Mechanical College Lytic peptides, use for growth, infection and cancer
WO1993003749A1 (en) 1991-08-21 1993-03-04 Board Of Regents, The University Of Texas System Methods and compositions for modulating g protein action
US5561107A (en) * 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
US5955573A (en) * 1993-06-04 1999-09-21 Demegen, Inc. Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
WO1995013085A1 (en) * 1993-11-08 1995-05-18 Demeter Biotechnologies Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
IL114697A0 (en) * 1994-07-22 1995-11-27 Demeter Biotech Ltd Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use
EP0932413A1 (en) * 1996-10-04 1999-08-04 Demegen, Inc. Method for treatment of immunodeficiency virus infection
DE19711831C2 (de) 1997-03-21 2000-07-13 Daimler Chrysler Ag Schmelzinfiltrierte faserverstärkte Verbundkeramik und Verfahren zur Herstellung einer solchen
AU6587998A (en) * 1997-03-27 1998-10-20 Demeter Biotechnologies, Ltd. Ligand/lytic peptide compositions and methods of use
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
HUP0202512A2 (hu) * 1999-08-09 2002-11-28 Tripep Ab Fehérjék polimerizációját gátló anyagok és eljárások ezek alkalmazására
EP2105141B1 (en) 2001-03-28 2012-08-08 Helix Biomedix, Inc. Short bioactive peptides and methods for their use
US7091185B2 (en) * 2003-02-24 2006-08-15 Dow Global Technologies Inc. Periodic antimicrobial peptides
GB0326393D0 (en) 2003-11-12 2003-12-17 Ares Trading Sa Cytokine antagonist molecules
US7288622B1 (en) * 2006-09-19 2007-10-30 Issar Pharmaceuticals Pvt Ltd Composition for treatment of burns and wounds
US7803755B2 (en) * 2006-12-21 2010-09-28 Jesse Jaynes Molecules for the treatment and prevention of fungal diseases
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
CN101485885B (zh) * 2009-01-09 2012-06-27 中国科学院广州生物医药与健康研究院 蛋白磷酸酯酶PPM1E作为疾病的治疗靶标及其应用和siRNA
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
US20120270770A1 (en) 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses
WO2012050892A2 (en) * 2010-09-29 2012-04-19 Esperance Pharmaceuticals, Inc. Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
US9487560B2 (en) 2013-05-02 2016-11-08 ISSAR Pharmaceuticals Ltd Angiogenic active lytic peptides
JP6613312B2 (ja) * 2014-10-14 2019-11-27 ジ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシズ 膵臓癌を処置するためのペプチドをベースとする方法
US9737584B2 (en) * 2015-08-11 2017-08-22 Issar Pharmaceuticals Composition for the treatment of burns, diabetic wounds, other types of wounds and subsequently greatly reduced scarring

Similar Documents

Publication Publication Date Title
FI3430027T3 (fi) Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa
PH12020552179A1 (en) Bicyclic peptide ligands specific for nectin-4
JP2018521983A5 (enExample)
JP2016527286A5 (enExample)
PH12020550929A1 (en) Bicyclic peptide ligands specific for epha2
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
JP2018521135A5 (enExample)
JP2017528419A5 (enExample)
JP2018523703A5 (enExample)
JP2017523781A5 (enExample)
TW201613958A (en) MIC-1 fusion proteins and uses thereof
MX2021013669A (es) Ligandos peptidicos biciclicos especificos para ox40.
JP2016509011A5 (enExample)
JP2018510132A5 (enExample)
JP2013172743A5 (enExample)
HRP20192174T1 (hr) Kombinirani farmaceutski pripravak
JP2015510393A5 (enExample)
JP2017503014A5 (enExample)
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
JP2012500001A5 (enExample)
MX2015016875A (es) Derivados de peptidos similares a peptido similar a glucagon 1 (glp-1) y sus usos.
JP2014526881A5 (enExample)
WO2016077505A3 (en) Targeted xten conjugate compositions and methods of making same
JP2016506413A5 (enExample)
EP4397374A3 (en) Improved peptide pharmaceuticals for insulin resistance